ABOS
What one share of Acumen Pharmaceuticals holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Alzheimer’s disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death.
Acumen Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.64 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.43 |
| Cash and investments | $1.52 |
| Debt | $0.44 |
| Book value | $0.79 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$17.48 | — | −$17.78 | — | −$44.36 |
| 2021 | — | −$5.02 | $0.00 | −$0.90 | — | — |
| 2022 | — | −$1.06 | $0.00 | −$0.87 | — | $4.60 |
| 2023 | — | −$1.08 | $0.00 | −$0.89 | — | $4.61 |
| 2024 | — | −$1.71 | $0.00 | −$1.44 | — | $3.03 |
| 2025 | — | −$2.00 | $0.00 | −$1.91 | — | $1.16 |